Allegro Names New CEO, Prepares Luminate for Phase III

August 31, 2018: By Jon Swedien

AllegroAllegro Ophthalmics has named Vicken Karageozian, MD, its new president and CEO.

Karageozian, an ophthalmic surgeon by training, co-founded the San Juan Capistrano, California, company and had been a senior executive at the firm.

He replaces fellow co-founder Hampar Karageozian, who has now been named the company’s executive chairman.

The move comes as Allegro prepares its lead compound, Luminate, for Phase III clinical trials in 2019.

Luminate is the brand name for risuteganib, an upstream broad-spectrum anti-integrin inhibitor that simultaneously inhibits four oxidative stress-induced pathways that contribute to retinal diseases such as DME and nonexudative age-related macular degeneration (dry AMD).

Luminate met its primary endpoint in a Phase IIb study when used as a sequential therapy in DME patients. The primary endpoint was non-inferiority to bevacizumab in mean change in best-corrected visual acuity at 20 weeks when Luminate was used with a single bevacizumab pretreatment (sequential therapy) or in combination with bevacizumab.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales